FDA Joint Advisory Committee Meeting on Dental Amalgam -- Septemb er 6-7, 2006

[Guest guest]

"Kuntze, M" <patricia.kuntze@...> wrote: From: "Kuntze, M" <patricia.kuntze@...>Subject: FDA Joint Advisory Committee Meeting on Dental Amalgam --Septemb er 6-7, 2006Date: Fri, 1 Sep 2006 19:25:59 -0400 Dear Colleague, This is to keep you updated on activities related to the upcoming Joint Meeting of the Dental Products Panel of the Medical Devices Advisory Committee of the Center for Devices and Radiological Health and the Peripheral and Central Nervous System Drugs Advisory Committee of the Center for Drug Evaluation and Research scheduled for September 6 and 7, 2006 at the Holiday Inn in Gaithersburg, MD.

This Joint Committee will review and discuss peer-reviewed scientific literature on dental amalgam and its potential mercury toxicity, specifically as it relates to neurotoxic effects. Today, the Food and Drug Administration (FDA) made the following documents related to this Joint Advisory Committee Meeting available for public review - Final Agenda; Briefing Information; Nature and Basis Statements of Conflict(s) of Interest; Final Questions; and Final Roster. These documents are available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfAdvisory/details.cfm?mtg=668 The Agency has opened a public docket for members of the public who are unable to attend the FDA Joint Advisory Committee meeting or for speakers

whose remarks might exceed the allotted time. This docket will be open until November 9, 2006. Comments posted to the docket are accessible to the public. You may submit comments electronically to FDADockets@... and reference Docket Number 2006N-0352 or visit http://www.fda.gov/dockets/ecomments, select "Docket Search," type in Docket Number 2006N-0352 under "Docket ID," and then follow the instructions provided. You can also send written comments to Dockets Management Branch (HFA-305), Food and Drug Administration,

5630 Fishers Lane, Room 1061, Rockville MD 20852. Please put the Docket Number 2006N-0352 on your comments. Thank you for your interest and participation in the activities of the Food and Drug Administration. As a reminder, please let me know if you do not wish to remain on this Outreach Network and we will promptly remove your email address from the list. Sincerely yours, M. Kuntze Senior Advisor for Consumer Affairs Food and Drug Administration